Magle Chemoswed Holding AB (publ) ("Magle Group" or the "Company") has received a decision from the Disciplinary Committee of Nasdaq Stockholm by which the Company is ordered to pay a fine corresponding to two (2) annual fees, amounting to approximately SEK 550 thousand, for breach of the Nasdaq First North Growth Market Rulebook and the EU Market Abuse Regulation ("MAR") concerning the Company's disclosure of an order received by its subsidiary Magle Biopolymers.
The Company disclosed a press release on 22 October 2025 regarding an order received by its subsidiary Magle Biopolymers. The Disciplinary Committee has found that the press release did not contain sufficient information regarding order value and the identity of the customer to enable a complete and correct assessment of the inside information by the public in accordance with MAR and the Nasdaq First North Growth Market Rulebook. The Company accepts the decision and acknowledges the deficiencies to which the matter relates and has since the event undertaken extensive measures to strengthen its internal controls regarding disclosure of information.
The full decision is available on Nasdaq Stockholm's website: https://www.nasdaq.com/market-regulation/nordic/stockholm/disciplinary/decisions-sanctions
Contacts
Aaron Wong, Interim CEO, CFO, phone +46 (0)76 664 35 79, aaron.wong@maglegroup.com
About Us
The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. Today, the Group includes two operational areas. Magle Chemoswed – a contract manufacturing organization (CMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle Biopolymers A/S - a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.com and www.maglebiopolymers.com
Redeye Nordic Growth AB is the company's Certified Adviser.